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Abstract
Background: Early diagnosis and prompt treatment including appropriate home-based treatment
of malaria is a major strategy for malaria control. A major determinant of clinical outcome in case
management is compliance and adherence to effective antimalarial regimen. Home-based malaria
treatment with inappropriate medicines is ineffective and there is insufficient evidence on how this
contributes to the outcome of severe malaria. This study evaluated the effects of pre-hospital
antimalarial drugs use on the presentation and outcome of severe malaria in children in Ibadan,
Nigeria.
Methods: Two hundred and sixty-eight children with a median age of 30 months comprising 114
children with cerebral malaria and 154 with severe malarial anaemia (as defined by WHO) were
prospectively enrolled. Data on socio-demographic data, treatments given at home, clinical course
and outcome of admission were collected and analysed.
Results: A total of 168 children had treatment with an antimalarial treatment at home before
presenting at the hospital when there was no improvement. There were no significant differences
in the haematocrit levels, parasite counts and nutritional status of the pre-hospital treated and
untreated groups. The most commonly used antimalarial medicine was chloroquine. Treatment
policy was revised to Artemesinin-based Combination Therapy (ACT) in 2005 as a response to
unacceptable levels of therapeutic failures with chloroquine, however chloroquine use remains
high. The risk of presenting as cerebral malaria was 1.63 times higher with pre-hospital use of
chloroquine for treatment of malaria, with a four-fold increase in the risk of mortality. Controlling
for other confounding factors including age and clinical severity, pre-hospital treatment with
chloroquine was an independent predictor of mortality.
Conclusion: This study showed that, home treatment with chloroquine significantly impacts on
the outcome of severe malaria. This finding underscores the need for wide-scale monitoring to
withdraw chloroquine from circulation in Nigeria and efforts intensified at promoting prompt
treatment with effective medicines in the community.
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Malaria remains a significant cause of morbidity and mor-
tality among children and creates enormous social, eco-
nomic and disease burdens in endemic regions[1,2].
Current control efforts focus on reducing malaria-attribut-
able morbidity and mortality. Prompt evaluation of all
febrile illness, case-recognition and use of appropriate
antimalarial therapy are essential to malarial control in
order to optimize clinical outcomes of malaria-infected
patients.
In Africa, majority of malaria episodes occur in rural areas
with considerable variation in the treatment seeking pat-
tern with over 50% self treated at home [3-5]. Self-treat-
ment with drugs bought from local private drug sellers has
been widely reported widely, ranging from between
4–87% of cases [3,6,7]. Help from the public health serv-
ices is usually sought only if the home based treatment is
considered ineffective [8,9]. The main reasons for these
delays are inaccessibility of the health services, limited
time, transport or financial constraints to visit them [10].
Although mothers and care-givers are able to recognize
symptoms associated with uncomplicated malaria, fewer
than 15% of episodes are treated correctly [11]. Patients
presenting with malaria often receive inappropriate drugs
or in incorrect doses in spite of trainings given to shop
keepers or care-givers in many communities [12]. Thus,
pre-hospital use of antimalarial drugs may also confound
some of the symptoms and signs that may be useful in
assessment and appropriate management decisions in the
hospital.
Drug resistance remains a major problem affecting
progress on management and control of malaria [13,14].
Chloroquine (CQ) resistance has been associated with
low drug accumulation [15]. The spread of decreasingly
sensitive Plasmodium falciparum may be promoted by the
presence of sub-curative concentrations of the antimalar-
ial medicine in the blood, that will only eliminate the
most sensitive parasites allowing those that are less sensi-
tive to survive [16], thus providing a biological advantage
to the parasite, allowing the spread of chloroquine resist-
ant forms [17]. Based on the efficacy profile of CQ, ACT
replaced CQ as the first line antimalarial medicine in
Nigeria in 2005. The new recommended first-line antima-
larial drug for home treatment is artemether-lumefantrine
(AL). Following deregulation of AL to an over-the-counter
(OTC) status, it is also the recommended option for com-
munity/home-based treatment of malaria. AL was distrib-
uted free for under-five children in many government
hospitals, however the supply remains irregular. However
in many areas, and even in government hospitals, CQ is
still being prescribed because of the high cost and unavail-
ability of AL. While many current programmes are pro-
moting home treatment of malaria, studies in Nigeria
have shown that antimalarials may be used inappropri-
ately even when prescribed in the hospital [13,14].
Many studies have evaluated the effects of different anti-
malarial chemoprophylaxis in Nigerian children, [19-21]
which resulted in severe morbidity in most cases and a
higher prevalence of malaria in the specific study areas.
However, the effects of inappropriate antimalarial taken
early in the course of a febrile illness has not been docu-
mented. Due to lack of availability and other constraints,
mothers and caregivers continue to use CQ in the initial
treatment of febrile episodes at home before seeking addi-
tional care when there is no improvement. Therefore, this
study was carried out to evaluate the effects of pre-hospi-
talization antimalarial drugs use on the morbidity and
outcome of severe malaria cases in children admitted to
the paediatric emergency units in Ibadan.
Methods
The study was carried out in Ibadan, south-west Nigeria, a
region that is exposed to stable, malaria transmission with
seasonal [1]. A total number of 268 children presenting
with fever, malaria parasitaemia and clinical features con-
sistent with the WHO [22] criteria of severe malarial anae-
mia (SMA) and cerebral malaria (CM) (without co-
morbidity, such as pneumonia or diarrhoea) were
recruited consecutively at the Children's Emergency Ward
and Children Out-Patient Clinic of the University College
Hospital, Ibadan and the Adeoyo Maternity Hospital,
Ibadan.
Ethical approval was obtained from the joint University of
Ibadan, University College Hospital, Ibadan Ethical Com-
mittee, the Oyo State Ministry of Health and the WHO
ethical review committee. Written informed consent was
obtained from the parents or guardian of the patients
prior to enrollment. A semi-structured questionnaire was
used to collect data on patients' demographic characteris-
tics, history of febrile illness, antimalarial drug treatments
given during current episode of clinical malaria prior to
presentation at the hospital and findings from physical
examination findings at the time of admission. All
patients had and clinical history and examination per-
formed, followed by blood films taken from finger pricks.
Malaria parasitaemia was confirmed with thick blood
smears stained with Giemsa examined for trophozoites of
P. falciparum independently by two trained and experi-
enced microscopists. Patients were managed on admis-
sion according to WHO guidelines and National
Antimalarial Policy.
Data was entered and analysed using SPSS 11.0 for Win-
dows (SPSS Inc., Chicago, USA). Descriptive statistics
(medians, ranges) were computed for continuous varia-
bles while frequencies were computed for categorical var-Page 2 of 6
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computed using Mann-Whitney U test because of their
non-parametric nature while comparisons of categorical
variables were done using the Fishers exact test because of
the small numbers in some subcategories. The logistic lin-
ear regression technique was used to investigate the pre-
dictive value of pre-hospital use of antimalarial and
outcome (died vs. survived) after inclusion of age and
clinical severity in the models. A p-value of < 0.05 was
taken as being statistically significant.
Results
The study patients comprised 155 (57.8%) male and 113
(42.2%) female giving a male to female ratio of 1.4:1. The
age of the patients ranged from five months to 10 years
with a median age of 30 months. One hundred and sixty
eight (62.7%) of the study population had pre-hospital
antimalarial treatments. Table 1 compared the age, hae-
matocrit, parasite counts and nutritional status of patients
who received and did not receive pre-hospital antimalar-
ial treatments. The median age of patients who had pre-
hospital treatment, 31.5 months was significantly higher
than 25.5 months in those who did not receive antimalar-
ial treatment (p = 0.013). There was no significant differ-
ence in the median haematocrit levels of the pre-hospital
treated and untreated group (p = 0.297). Though a higher
malaria parasite counts was found in the group of patients
who did not receive pre-hospital antimalarial drugs but
this did not differ significantly from the parasite counts
estimate in the group who received pre-hospital treat-
ments (p = 0.837).
Of the 268 patients with severe malaria, 114 (42.5%)
were cases of CM while 154 (57.5%) had SMA without
coma (Table 2). A significantly higher proportion of CM
(71.1%) than SMA (56.5%) patients had antimalarial
drugs before presenting in the hospital (p = 0.016). There
was no significant gender difference in the distribution of
patients in respect of treatment given before presentation
(p = 0.371). Although about two-thirds (61.9%) of the
study patients came from the lower socioeconomic class
family but there was no significant difference in the distri-
bution of patients who had pre-hospital antimalarial
treatment between upper and lower classes (p = 0.606).
CQ was the most commonly used antimalarial drug
accounting for 54.2% of the children who received anti-
malarial treatment. CQ was given to 49 (43.0%) and 42
(27.3%) of CM and SMA, respectively (p = 0.009). Amo-
diaquine was given to 12 (10.5%) of CM and 8 (5.2%) of
SMA groups. Sulphadoxine-pyrimethamine was given to 7
(6.1%) of CM patients and six (3.9%) of SMA patients. Of
the 168 children who received an antimalarial drug before
admission, 48.2% had CM compared with 33% in the
group of patient who had no antimalarial treatment (p =
0.015, RR = 1.26). Table 3 shows that 49 (53.8%) children
out of 91 who had CQ treatment compared with 33
(33.0%) in the no treatment group developed CM. The








n % N %
Gender
Male 101 65.2 54 34.8 1.10 
(0.91, 1.33)
0.371
Female 67 59.3 46 40.7
Diagnosis
CM 81 71.1 33 28.9 1.26 
(1.05, 1.51)
0.016
SMA 87 56.5 67 43.5
Social Class
Lower 102 61.4 64 38.6 0.95 
(0.79, 1.15)
0.606
Upper 66 64.7 36 35.3
CM – Cerebral malaria, SMA- Severe malarial anaemia, OR-Odds ratio
*Fishers exact test used
Table 1: Comparisons of age, parasite counts and haematocrit
Treatment given
N = 168




Range 5–120 5–120 6875.0 0.013
Median 31.5 25.5
Haematocrit (%)
Range 5–34 6–35 7449.5 0.297
Median 18 16
Parasite counts (/μl)
Median 4137142 768000 8092.5 0.837
Nutritional status
Range -6.37–2.90 -8.95–1.91 7962.5 0.635
Median -1.38 -1.25Page 3 of 6
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was treated with CQ at home. Table 4 shows the outcome
of the severe malaria cases and compared the proportion
of those who had pre-hospital antimalarial drugs among
those that survived and those that died. The overall mor-
tality rate of severe malaria was 6.7%. Two-thirds of the
children who died had pre-hospital treatment with CQ.
Table 5 shows the logistic regression model for potential
predictors of death in severe malaria. Controlling for age
and clinical severity (CM or SMA), pre-hospital treatment
with CQ remained a significant predictor of death. The
risk of death was four times higher if a child had been
given CQ before presentation than if he had no pre-hos-
pital treatment with CQ.
Discussion
Early treatment with effective antimalarial treatment has
been demonstrated to decrease the morbidity and mortal-
ity of malaria in endemic countries. In most countries in
the sub-Saharan Africa however, there has been little suc-
cess in reducing both infant and child mortality even with
the focus on better management of malaria. The present
study has shown that pre-hospital antimalarial treatment
of febrile children remains a significant practice among
child care-givers in Nigeria as previously reported from
the same area [11]. The prevalence of CQ use, 54.2% in
this present study, is high despite the recent National drug
policy change from CQ to ACTs.
Pre-hospital administration of pre-packaged chloroquine
was previously reported to have reduced the risk of devel-
oping severe malaria among children in some African
communities at a time when CQ was still effective [23].
Our data has shown that pre-hospital administered CQ
was associated with an increased risk of severe malaria,
with a concurrent increase in mortality. This may be due
to a recent upsurge in the incidence of CQ resistance
malaria in Nigeria. This findings corroborates a recent
report by Sowunmi and co-workers [24] that observed
failure to clear parasites within three days and the preva-
lence of fever two days after commencement of CQ were
strong indicators or predictors of malaria treatment failure
in Nigerian children.
However, in a previous report from the same centre, CQ
resistance of P. falciparum in vitro was significantly higher
in isolates from patients with severe malaria than those
with uncomplicated disease [13]. The clinical implication
of these findings was that severe malaria patients were less
likely to respond to CQ than cases of uncomplicated
malaria and this association was thought to be due to
either progression of uncomplicated to severe disease fol-
lowing CQ failure or increased virulence of CQ resistant
parasites. In the light of the findings from this study, CQ
resistance was a determinant of malaria severity and mor-
tality which may be due to the selection of increasingly
virulent CQ resistant forms promoted by the presence of
sub-curative concentrations of the antimalarial drug in the
Table 5: Logistic regression model for potential predictors of 
outcomes in severe malaria
Factors B S.E p Exp(β) 95% CI
Chlorquine 
(given vs not given)
1.367 0.528 0.010 3.923 1.39, 11.05
Age (months) 0.008 0.012 0.512 1.008 0.98, 1.03
CM vs SMA 0.903 0.532 0.089 2.467 0.87, 6.99
Constant -1.939 1.512 0.200 0.144 -
Table 3: Diagnoses by chloroquine use and no pre-hospital 
treatment given
Drug Given Chloroquine No treatment given Total
CM 49 53.8 33 33.0 82 42.9
SMA 42 46.2 67 67.0 109 57.1
Total 91 100.0 100 100.0 191 100.0
P = 0.005, RR = 1.63, 95% CI = 1.16, 2.29
Fishers exact test used
Table 4: Risk of death in severe malaria after pre-hospital antimalarial drugs
Antimalarial drugs Died (18) Survived (250) RR(95% CI) *p
n % n %
Chloroquine 12 66.7 79 31.6 4.25(1.54–11.7) 0.004
Amodiaquine 2 11.1 17 6.8 1.71(0.36–8.07) 0.371
Sulfadoxine-pyrimethamine 1 5.6 11 4.4 1.33(0.16–10.93) 0.559
Quinine 1 5.6 0 0.0 - 0.067
Halofanthrin 1 5.6 2 0.8 7.29(0.62–84.5) 0.189
Artesunate only 1 5.6 1 0.4 14.6(0.87–24.5) 0.130
*Fishers exact test usedPage 4 of 6
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allowing those that are less sensitive to survive [17].
A recent study from Nigeria has shown that correct use of
chloroquine increased from 2.6% to 52.3% among home
care-givers after training, however as high as 47.7% still
wrongly treat febrile children [12]. This finding under-
scores the need to review the present policy on home
management of malaria. If this is not adequately
addressed, even the use of more efficacious antimalarials
like the ACTs, still poses a risk to effective home based
management of malaria at the community level.
In addition, there is some evidence to suggest that house-
holds of a high social class are more likely to use antima-
larials to which there is less parasite resistance. As majority
of our patients were from lower socioeconomic class,
reducing the cost, improving the availability and access to
quality pre-packaged artemisinin-based antimalarial may
improve pre-hospital treatment of malaria and thus pre-
vent resistance [25]. White [26] observed that the main
obstacles to the success of combination treatment in pre-
venting the emergence and spread of resistance, is incom-
plete or inadequate treatment. Thus, factors such as
availability, wide coverage of good quality drugs and ade-
quate antimalarial treatment regimens need to taken into
cognizance to prevent emergence of resistance to ACTs.
Furthermore, early diagnosis and prompt treatment are
major strategies for malaria control. In the light of our
findings, early treatment with ineffective medicines can
result in worse outcome.
In conclusion, the use of ineffective antimalarial medi-
cines for the home-based management of malaria could
be a hindrance to prompt access to effective treatment, as
the caregivers delay seeking treatment convinced they
have initiated antimalarial treatment, albeit with compro-
mised medicines. This study has demonstrated this prac-
tise to be deleterious on the outcome of malaria. To
maximise the impact of chemotherapy on malaria mor-
bidity and mortality, resources are urgently required to
facilitate the use of ACTs for home-based treatment of
malaria.
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